Rosoxacin
From Wikipedia, the free encyclopedia
|
Rosoxacin
|
|
| Systematic (IUPAC) name | |
| 1-Ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C17H14N2O3 |
| Mol. mass | 294.30 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Rosoxacin (also known as acrosoxacin, tradename Eradacil) is a quinolone antibiotic indicated for the treatment of urinary tract infections and certain sexually transmitted diseases. Rosoxacin is not available in the United States.
It was developed by Sanofi-Synthelabo (now part of sanofi-aventis).
|
|||||||||||

